Matches in SemOpenAlex for { <https://semopenalex.org/work/W27859800> ?p ?o ?g. }
- W27859800 endingPage "B4506" @default.
- W27859800 startingPage "B4506" @default.
- W27859800 abstract "Cardiovascular disease is the number one cause of death globally, and atherothrombosis is the underlying cause of most cardiovascular events. Several studies have shown that antiplatelet therapy, including aspirin (acetylsalicylic acid), reduces the risk of cardiovascular events and death. However, it is well-known that many patients experience cardiovascular events despite treatment with aspirin, often termed aspirin low-responsiveness. This fact has caused considerable debate: does biochemical aspirin low-responsiveness have prognostic value? Can low-responders be reliably identified? And if so, should antithrombotic treatment be changed? Is the whole discussion of antiplatelet drug response merely a result of low compliance? Compliance should be carefully optimised, before evaluating the pharmacological effect of a drug. It is well-known that cardiovascular disease is multifactorial, and, therefore, total risk reduction is not feasible. Aetiological factors to the variable platelet inhibition by aspirin seem to include genetic factors, pharmacological interactions, smoking, diabetes mellitus, and increased platelet turnover. It is a captivating thought that antiplatelet therapy may be improved by individually tailored therapy based on platelet function testing. Ongoing studies are challenging the current one-size-fits-all dosing strategy, but the preceding evaluation of platelet function assays has not been adequate. The overall objective of this thesis was to evaluate the reproducibility of and aggreement between a number of widely used platelet function tests and to explore the importance of platelet turnover for the antiplatelet effect of aspirin in patients with coronary artery disease. In the intervention studies (studies 1, 3, and 4), optimal compliance was confirmed by measurements of serum thromboxane, which is the most sensitive assay to confirm compliance with aspirin. In study 1, platelet function tests widely used to measure the antiplatelet effect of aspirin were evaluated in healthy individuals and patients with coronary artery disease. Pharmaco-specific metabolites were measured in urine and serum to investigate the pharmacodynamic effect of aspirin and to enable the comparison with the more global tests of platelet function. Based on repeated duplicate measurements, we evaluated the reproducibility of each test. We found that reproducibility of the classical reference method was not impressive and that the newer, so-called point-of-care tests differed markedly on reproducibility. With coefficients of variation of about 3%, the VerifyNow Aspirin test was clearly the most reproducible test - even after correction of the official scale, which begins at about 350 aspirin reaction units and, therefore, results in artificially low coefficients of variation. Among the platelet function tests investigated, Multiplate was most sensitive for aspirin treatment. In study 2 we performed the hitherto largest study of newly released, immature platelets as a marker of platelet turnover. The study population included healthy individuals, patients with stable coronary artery disease, and patients with acute coronary syndromes. The main finding was an increased fraction of immature platelets in patients with ST-segment myocardial infarction, indicating an increased platelet turnover. Smoking and type 2 diabetes were identified as independent determinants of platelet turnover. In study 3 we explored the relationship between platelet turnover and the antiplatelet effect of aspirin in patients with stable coronary artery disease. The study results support the hypothesis that an increased platelet turnover reduces the antiplatelet effect of aspirin. The main findings were: 1) platelet turnover correlated with platelet aggregation measured by Multiplate and with sP-selectin, a marker of platelet activation. 2) Patients with diabetes mellitus type 2 had reduced antiplatelet effect of aspirin compared with patients without diabetes. 3) Widely used platelet function tests differ with respect to dependence on platelet parameters, including platelet count. 4) Smoking, diabetes mellitus type 2, and thrombopoietin were identified as independent determinants of platelet turnover. 5) The relative fraction of immature platelets has been employed in most previous studies, but in stable patients the absolute immature platelet count does not seem dependent on the total platelet count, and it has a stronger correlation with both platelet activation measured by sP-selectin and with platelet aggregation during treatment with aspirin. In study 4 we investigated platelet turnover and the antiplatelet effect of aspirin in a nested case-control study on patients with previous definite stent thrombosis. Patients with stent thrombosis were compared with patients without stent thrombosis, with whom they were matched at a 1:2 ratio with respect to risk factors for stent thrombosis: age, sex, stent type, and indication for percutaneous coronary intervention. The study showed that patients with previous stent thrombosis have reduced antiplatelet effect of aspirin and a tendency towards increased platelet turnover. In conclusion, widely used platelet function tests markedly differ on reproducibility, and the agreement between tests is relatively poor. An increased platelet turnover as suggested by the presence of newly formed immature platelets is important for the antiplatelet effect of aspirin, and, perhaps also for the development of acute coronary thrombosis. In the future, individually tailored antiplatelet therapy may potentially improve the benefit-risk ratio of antiplatelet therapy." @default.
- W27859800 created "2016-06-24" @default.
- W27859800 creator A5013553039 @default.
- W27859800 date "2012-09-01" @default.
- W27859800 modified "2023-09-23" @default.
- W27859800 title "Antiplatelet effect of aspirin in patients with coronary artery disease." @default.
- W27859800 cites W107715711 @default.
- W27859800 cites W1409766979 @default.
- W27859800 cites W146113912 @default.
- W27859800 cites W1489412054 @default.
- W27859800 cites W1490597531 @default.
- W27859800 cites W1501290200 @default.
- W27859800 cites W1502078581 @default.
- W27859800 cites W1510658613 @default.
- W27859800 cites W1518382227 @default.
- W27859800 cites W1518533198 @default.
- W27859800 cites W153925048 @default.
- W27859800 cites W1573261868 @default.
- W27859800 cites W1591788256 @default.
- W27859800 cites W1726466368 @default.
- W27859800 cites W1843026349 @default.
- W27859800 cites W1918341369 @default.
- W27859800 cites W1928088046 @default.
- W27859800 cites W193961006 @default.
- W27859800 cites W1964095591 @default.
- W27859800 cites W1964457971 @default.
- W27859800 cites W1965891833 @default.
- W27859800 cites W1967561904 @default.
- W27859800 cites W1968931774 @default.
- W27859800 cites W1969257934 @default.
- W27859800 cites W1970493523 @default.
- W27859800 cites W1970616328 @default.
- W27859800 cites W1971204967 @default.
- W27859800 cites W1974478868 @default.
- W27859800 cites W1974742589 @default.
- W27859800 cites W1978196679 @default.
- W27859800 cites W1978995142 @default.
- W27859800 cites W1981260144 @default.
- W27859800 cites W1981744980 @default.
- W27859800 cites W1983380547 @default.
- W27859800 cites W1983759759 @default.
- W27859800 cites W1985142448 @default.
- W27859800 cites W1985491210 @default.
- W27859800 cites W1986040306 @default.
- W27859800 cites W1986073508 @default.
- W27859800 cites W1987143431 @default.
- W27859800 cites W1988143463 @default.
- W27859800 cites W1988516002 @default.
- W27859800 cites W1989615944 @default.
- W27859800 cites W1989937057 @default.
- W27859800 cites W1990031788 @default.
- W27859800 cites W1990149423 @default.
- W27859800 cites W1992447985 @default.
- W27859800 cites W1993279140 @default.
- W27859800 cites W1997343401 @default.
- W27859800 cites W1997534509 @default.
- W27859800 cites W1997719795 @default.
- W27859800 cites W2001738758 @default.
- W27859800 cites W2002018517 @default.
- W27859800 cites W2002631201 @default.
- W27859800 cites W2003583128 @default.
- W27859800 cites W2004556615 @default.
- W27859800 cites W2005821429 @default.
- W27859800 cites W2007152663 @default.
- W27859800 cites W2007745737 @default.
- W27859800 cites W2008574207 @default.
- W27859800 cites W2009461799 @default.
- W27859800 cites W2009628393 @default.
- W27859800 cites W2010970094 @default.
- W27859800 cites W2011327495 @default.
- W27859800 cites W2011579224 @default.
- W27859800 cites W2011863243 @default.
- W27859800 cites W2012822212 @default.
- W27859800 cites W2014644245 @default.
- W27859800 cites W2015795623 @default.
- W27859800 cites W2017361145 @default.
- W27859800 cites W2017453532 @default.
- W27859800 cites W2018828288 @default.
- W27859800 cites W2019608889 @default.
- W27859800 cites W2020264773 @default.
- W27859800 cites W2020789281 @default.
- W27859800 cites W2020960046 @default.
- W27859800 cites W2021732224 @default.
- W27859800 cites W2022200370 @default.
- W27859800 cites W2022965893 @default.
- W27859800 cites W2023520096 @default.
- W27859800 cites W2024352468 @default.
- W27859800 cites W2024586028 @default.
- W27859800 cites W2025377307 @default.
- W27859800 cites W2026418140 @default.
- W27859800 cites W2027031916 @default.
- W27859800 cites W2027106701 @default.
- W27859800 cites W2027436660 @default.
- W27859800 cites W2028430410 @default.
- W27859800 cites W2029363362 @default.
- W27859800 cites W2030977683 @default.
- W27859800 cites W2032891603 @default.
- W27859800 cites W2033191496 @default.